DIL Dyadic International

Dyadic International, Inc. (AMEX: DIL), a biotechnology company engaged in the development, manufacture and sale of biological products, today announced that its President and CEO, Mark Emalfarb, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference. The presentation is scheduled to take place at 4:35 p.m. EST on Tuesday, November 8, 2005, at the New York Palace Hotel in New York, NY. About Dyadic Dyadic International, Inc., is engaged in the development, manufacture and sale of biological products (proteins, enzymes, peptides and other bio-molecules), as well as the licensing of its enabling proprietary technology to business collaborators for the discovery, development and manufacture of biological products from genes. Dyadic markets its products and services for applications in the textile, chemical, agricultural, pulp & paper, pharmaceutical, biotechnology and other industries, using its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production of biological products. Cautionary Statement for Forward-Looking Statements Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, and our Quarterly Report for the quarter ended June 30, 2005 on Form 10-QSB. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.